Clinical trial
Safety and Efficacy Study of CF101 to Treat Psoriasis
NCT00428974 · Can-Fite BioPharma, Industry · Completed
Key facts
| NCT number | NCT00428974 |
|---|---|
| Title | Safety and Efficacy Study of CF101 to Treat Psoriasis |
| Official title | A Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of the Safety and Activity of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis |
| Lead sponsor | Can-Fite BioPharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Plaque Psoriasis |
| Intervention type | Drug |
| Interventions | CF101 1mg, CF101 2mg, CF101 4mg, Placebo |
| Enrollment | 76 |
| Start date | Jun 1, 2007 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Jan 30, 2007 |
| Last update posted | Feb 8, 2023 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: